Evaluation of Treatment Outcomes Among Individuals on Highly Active Antiretroviral Therapy in KwaZulu-Natal, South Africa

Overview

Journal AIDS Res Treat

Publisher Wiley

Specialty Infectious Diseases

Date 2024 Dec 18

PMID 39691492

Authors

Tambwe Willy Muzumbukilwa

Riziki Ghislain Manimani

Aganze Gloire-Aime Mushebenge

Rajesh Vikram Vagiri

Manimbulu Nlooto

Affiliations

Soon will be listed here.

Abstract

Despite access to antiretroviral therapy (ART), South Africa has a high human immunodeficiency virus (HIV) burden. Treatment outcomes among individuals on highly active ART (HAART) in KwaZulu-Natal, with a higher incidence of HIV, are not fully known. This study evaluated the impact of HAART outcomes and identified and analyzed the factors associated with the outcomes in people living with HIV and AIDS (PLWHA) in the high-incidence region of KwaZulu-Natal Province, South Africa. This retrospective medical record review was conducted at King Edward VIII Hospital in South Africa. Data analysis was performed using STATA software Version 18.0 and Microsoft Excel 2021. The estimates used were 95% confidence intervals, and a value < 0.05 was considered statistically significant. A total of 707 clinical records of PLWHA were examined and analyzed; less than half of them (44.98%, = 318) achieved the benchmark of two consecutive instances of suppressed viral loads. The CD4 greater than or equal to 500 cells/mm at baseline average of 22.91% ( = 162) registered an increase to 48.94% ( = 346) in the 6 month and further escalated to 79.49% ( = 562) by the 12 month following ART initiation. A total of 160 deaths (mortality rate of 22.63%) were recorded within the study period. The percentage of HIV-infected patients attaining viral suppression at 6 and 12 months after initiating the treatment was respectively 44.98% and 67.04%, below the 90% target established by the Joint United Nations Program on HIV/AIDS (UNAIDS). The proportion of favorable immunological responses for individuals on ART increased over time.

References

Puryear S, Balzer L, Ayieko J, Kwarisiima D, Hahn J, Charlebois E . Associations between alcohol use and HIV care cascade outcomes among adults undergoing population-based HIV testing in East Africa. AIDS. 2019; 34(3):405-413. PMC: 7046088. DOI: 10.1097/QAD.0000000000002427. View

Ladak F, Socias E, Nolan S, Dong H, Kerr T, Wood E . Substance use patterns and HIV-1 RNA viral load rebound among HIV-positive illicit drug users in a Canadian setting. Antivir Ther. 2018; 24(1):19-25. PMC: 6455806. DOI: 10.3851/IMP3265. View

Fiseha T, Ebrahim H, Ebrahim E, Gebreweld A . CD4+ cell count recovery after initiation of antiretroviral therapy in HIV-infected Ethiopian adults. PLoS One. 2022; 17(3):e0265740. PMC: 8947242. DOI: 10.1371/journal.pone.0265740. View

Opoku S, Sakyi S, Ayisi-Boateng N, Enimil A, Senu E, Ansah R . Factors associated with viral suppression and rebound among adult HIV patients on treatment: a retrospective study in Ghana. AIDS Res Ther. 2022; 19(1):21. PMC: 9131580. DOI: 10.1186/s12981-022-00447-2. View

Katirayi L, Chadambuka A, Muchedzi A, Ahimbisibwe A, Musarandega R, Woelk G . Echoes of old HIV paradigms: reassessing the problem of engaging men in HIV testing and treatment through women's perspectives. Reprod Health. 2017; 14(1):124. PMC: 5629810. DOI: 10.1186/s12978-017-0387-1. View

Lilian R, Rees K, McIntyre J, Struthers H, Peters R . Same-day antiretroviral therapy initiation for HIV-infected adults in South Africa: Analysis of routine data. PLoS One. 2020; 15(1):e0227572. PMC: 6959580. DOI: 10.1371/journal.pone.0227572. View

Okonji E, van Wyk B, Mukumbang F, Hughes G . Determinants of viral suppression among adolescents on antiretroviral treatment in Ehlanzeni district, South Africa: a cross-sectional analysis. AIDS Res Ther. 2021; 18(1):66. PMC: 8501534. DOI: 10.1186/s12981-021-00391-7. View

Wakooko P, Gavamukulya Y, Wandabwa J . Viral load Suppression and Associated Factors among HIV Patients on Antiretroviral Treatment in Bulambuli District, Eastern Uganda: A Retrospective Cohort Study. Infect Dis (Auckl). 2020; 13:1178633720970632. PMC: 7656881. DOI: 10.1177/1178633720970632. View

Scheibe A, Young K, Versfeld A, Spearman C, Sonderup M, Prabdial-Sing N . Hepatitis B, hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in South Africa: findings from a seven-city cross-sectional survey (2017). BMC Infect Dis. 2020; 20(1):655. PMC: 7475946. DOI: 10.1186/s12879-020-05359-y. View

10.

Fontela C, Aguinaga A, Moreno-Iribas C, Reparaz J, Rivero M, Gracia M . Trends and causes of mortality in a population-based cohort of HIV-infected adults in Spain: comparison with the general population. Sci Rep. 2020; 10(1):8922. PMC: 7265289. DOI: 10.1038/s41598-020-65841-0. View

11.

Billioux A, Nakigozi G, Newell K, Chang L, Quinn T, Gray R . Durable Suppression of HIV-1 after Virologic Monitoring-Based Antiretroviral Adherence Counseling in Rakai, Uganda. PLoS One. 2015; 10(5):e0127235. PMC: 4444255. DOI: 10.1371/journal.pone.0127235. View

12.

Gandhi R, Spritzler J, Chan E, Asmuth D, Rodriguez B, Merigan T . Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr. 2006; 42(4):426-34. DOI: 10.1097/01.qai.0000226789.51992.3f. View

13.

Bello K, Mesner O, OBryan T, Won S, Lalani T, Ganesan A . Factors associated with 10 years of continuous viral load suppression on HAART. BMC Infect Dis. 2016; 16:351. PMC: 4957300. DOI: 10.1186/s12879-016-1677-x. View

14.

Staupe-Delgado R, Rubin O . Living through and with the global HIV/AIDS pandemic: Distinct 'pandemic practices' and temporalities. Soc Sci Med. 2022; 296:114809. PMC: 8837471. DOI: 10.1016/j.socscimed.2022.114809. View

15.

Kharsany A, Cawood C, Lewis L, Yende-Zuma N, Khanyile D, Puren A . Trends in HIV Prevention, Treatment, and Incidence in a Hyperendemic Area of KwaZulu-Natal, South Africa. JAMA Netw Open. 2019; 2(11):e1914378. PMC: 6826647. DOI: 10.1001/jamanetworkopen.2019.14378. View

16.

Youness A, Miquel C, Guery J . Escape from X Chromosome Inactivation and the Female Predominance in Autoimmune Diseases. Int J Mol Sci. 2021; 22(3). PMC: 7865432. DOI: 10.3390/ijms22031114. View

17.

Bisson G, Ramchandani R, Miyahara S, Mngqibisa R, Matoga M, Ngongondo M . Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults. AIDS. 2017; 31(16):2217-2225. PMC: 5633516. DOI: 10.1097/QAD.0000000000001606. View

18.

Jobanputra K, Parker L, Azih C, Okello V, Maphalala G, Kershberger B . Factors associated with virological failure and suppression after enhanced adherence counselling, in children, adolescents and adults on antiretroviral therapy for HIV in Swaziland. PLoS One. 2015; 10(2):e0116144. PMC: 4335028. DOI: 10.1371/journal.pone.0116144. View

19.

Crepaz N, Song R, Lyss S, Hall H . Estimated time from HIV infection to diagnosis and diagnosis to first viral suppression during 2014-2018. AIDS. 2021; 35(13):2181-2190. PMC: 9647140. DOI: 10.1097/QAD.0000000000003008. View

20.

Cherutich P, Kim A, Kellogg T, Sherr K, Waruru A, De Cock K . Detectable HIV Viral Load in Kenya: Data from a Population-Based Survey. PLoS One. 2016; 11(5):e0154318. PMC: 4871583. DOI: 10.1371/journal.pone.0154318. View